Cost effectiveness of sorafenib for second line treatment of advanced renal cell carcinoma

Authors: Professor Jo Thompson-Coon , Green C, Hoyle M, Liu Z, Welch K
Published: 25th September 2009
Theme: Complex Care
Type: Paper
DOI: 10.1111/j.1524-4733.2009.00616.x

Reference:

Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, Stein K. Cost effectiveness of sorafenib for second line treatment of advanced renal cell carcinoma. Value in Health 2010;13(1): 55-60.